Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
Level 5 - mechanism / opinion, no new human data
Preclinical animal study with no human data.
PubMed 20473919 · doi:10.1002/ijc.25431
What was done
Researchers evaluated the antimetastatic effects of 6-diazo-5-oxo-L-norleucine (DON), a glutamine analog, using the VM-M3 murine model of systemic metastasis. Primary tumor growth and metastatic spread to the liver, lung, and kidney were assessed using bioluminescence imaging and histology in DON-treated mice compared to untreated controls.
What was found
Primary tumor growth was approximately 20-fold lower in DON-treated mice compared to untreated controls. Treatment with DON also inhibited metastasis to the liver, lung, and kidney.
Why it matters
This paper provides preclinical proof of concept that targeting glutamine metabolism can suppress both primary tumor progression and systemic metastatic dissemination in a mouse model.
Limits
The study is limited to a single preclinical mouse model (VM-M3) and cannot be directly translated to human clinical efficacy. The abstract reports no sample sizes (n), dosing regimens, toxicity outcomes, survival metrics, or exact quantitative values/confidence intervals for metastatic burden.
Cited by
- partial Metastatic cancer cells are driven by glutamine and require glucose to fuel their growth.